| 主な論文 |
- DeCaprio, JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica-Worms H, Huang C-M, Livingston DM. The product of retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58: 1085-1095, 1989
- Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y, Griffin JD. Cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science 250: 805-808, 1990
- DeCaprio JA, Furukawa Y, Ajchenbaum F, Griffin JD, Livingston DM. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci USA 89: 1795-1798, 1992
- Kikuchi J, Furukawa Y, Iwase S, Terui Y, Nakamura M, Kitagawa S, Kitagawa M, Komatsu N, Miura Y. Polyploidization and functional maturation are two distinct processes during megakaryocytic differentiation: Involvement of cyclin-dependent kinase inhibitor p21 in polyploidization. Blood 89: 3980-3990, 1997
- Furukawa Y, Iwase S, Kikuchi J, Nakamura M, Yamada, H, Matsuda, M. Transcriptional repression of the E2F-1 gene by interferon-α Is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes. Oncogene 18: 2003-2014, 1999
- Kawasaki A, Matsumura I, Miyagawa J, Ezoe S, Tanaka H, Terada Y, Tatsuka M, Machii T, Miyazaki H, Furukawa Y, Kanakura Y. Downregulation of an AIM-1 kinase couples with megakaryocytic polyploidization of human hematopoietic cells. J Cell Biol 152: 275-287, 2001
- Kano Y, Akutsu M, Mano H, Sato Y, Tsunoda S, Homma Y, Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999-2007, 2001
- Ishii H, Inageta T, Mimori K, Saito T, Sasaki H, Isobe M, Mori M, Croce CM, Huebner K, Ozawa K, Furukawa Y. Frag1, a homolog of alternative replication factor C subunits, links replication stress surveillance with apoptosis. Proc Natl Acad Sci USA 102: 9655-9660, 2005
- Sekiya M, Osuga J, Nagashima S, Ohshiro T, Igarashi M, Okazaki H, Takahashi M, Tazoe F, Wada T, Ohta K, Takanashi M, Kumagai M, Nishi M, Takase S, Yahagi N, Yagyu H, Ohashi K, Nagai R, Kadowaki T, Furukawa Y, Ishibashi S. Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis. Cell Metabolism 10: 219-228, 2009
- Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y. Expression Levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J Biol Chem 284: 30673-30683, 2009
- Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K, Nobuyoshi M, Ozawa K, Kano Y, Furukawa, Y. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 116: 406-417, 2010
- Wada T, Kikuchi J, Furukawa Y. Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Rep 13: 142-149, 2012
- Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest 125: 4375-4390, 2015
- Wada T, Koyama D, Kikuchi J, Honda H, Furukawa Y. Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. Blood 125: 3731-3746, 2015
- Kikuchi J, Kuroda Y, Koyama D, Osada N, Izumi T, Yasui H, Ichinohe T, Furukawa Y. Myeloma cells are activated in bone marrow microenvironment by the CD180/MD-1 complex, which senses lipopolysaccharide. Cancer Res 78: 1766-1778, 2018
- Saito S, Kikuchi J, Koyama D, Sato S, Koyama H, Osada N, Kuroda Y, Akahane K, Inukai T, Umehara T, Furukawa Y. Eradication of central nervous system leukemia of T-cell origin with a brain-permeable LSD1 inhibitor. Clin Cancer Res 25: 1601-1611, 2019
- Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, Koyama D, Izumi T, Yasui H, Suzuki A, Furukawa Y. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia 34: 180-195, 2020
- Osada N, Kikuchi J, Koyama D, Kuroda Y, Yasui H, Leverson JD, Furukawa Y. mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation. Haematologica 106: 3008-3013, 2021
- Kikuchi J, Kodama N, Takeshita M, Hijima T, Ikeda S, Kobayashi T, Kuroda Y, Uchiyama M, Osada N, Bogen B, Yasui H, Takahashi N, Miwa A, Furukawa Y. EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress. Blood Adv 7: 508-524, 2023
- Osada N, Kikuchi J, Iha H, Yasui H, Ikeda S, Takahashi N, Furukawa Y. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma. Clin. Transl. Med. 13: e1364, 2023
- Matsuoka S, Osada N, Kubota H, Kikuzato K, Koyama H, Sonoda T, Idei A, Yoshida M, Kikuchi M, Umehara T, Watanabe C, Honma T, Yasui H, Ikeda S, Takahashi N, Nakasone H, Kikuchi J, Furukawa Y. Discovery of a novel class NSD2 inhibitor for t(4;14)-positive multiple myeloma. Blood Neoplasia, published online on March 11, 2025
- 全論文リスト：こちらから
|
